RedHill Biopharma reported $2.87M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Cara Therapeutics USD 20.73M 684K Dec/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
Cronos Group USD 791.79M 7.62M Dec/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025